Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner

Current Biology

Volumn 9, Issue 12, 1999, Pages 622-631

  Lama, Juan ^a   Mangasarian, Aram ^b   Trono, Didier ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033578072     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(99)80284-X     Document Type: Article

References (66)

1. Klatzmann D, Champagne E, Chamaret S, Gruest D, Hercend T, et al.: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
2. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
3. Maddon P, Dalgleish AG, McDougal JS, Clapham P, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348.
4. Stein BS, Gowda SD, Lifson JD, Penhallow RC, Bensch KG, Engleman EG: pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 1987, 49:659-668.
5. Wilkinson D: Cofactors provide the entry keys. Curr Biol 1996, 6:1051-1053.
6. Salmon P, Olivier R, Riviere Y, Brisson E, Gluckman JC, Kieny MP, et al.: Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication. J Exp Med 1988, 168:1953-1969.
7. Guy B, Kieny MP, Riviere Y, Le Peuch C, Dott K, Girard M, et al.: HIV F/3′ orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 1987, 330:266-269.
8. Garcia JV, Miller AD: Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991, 350:508-511.
9. Stevenson M, Meier C, Mann AM, Chapman N, Wasiak A: Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS. Cell 1988, 53:483-496.
10. Willey RL, Maldarelli F, Martin MA, Strebel K: Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992, 66:7193-7200.
11. Kim SY, Byrn R, Groopman J, Baltimore D: Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 1989, 63:3708-3713.
12. Klotman ME, Kim S, DeRossi A, Baltimore D, Wong-Staal F: Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci USA 1991, 88:5011 -5015. [Erratum Proc Natl Acad Sci USA 1992, 89:1148].
13. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D: Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994, 76:853-864.
14. Rhee SS, Marsh JW: Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol 1994, 68:5156-5163.
15. Schwartz O, et al.: Human immunodeficiency virus type 1 Nef induces accumulation of CD4 in early endosomes. J Virol 1995, 69:528-533.
16. Schwartz S, Felber BK, Fenyo EM, Pavlakis GN: Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol 1990, 64:5448-5456.
17. Crise B, Buonocore L, Rose JK: CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol 1990, 64:5585-5593.
18. Jabbar MA, Nayak DP: Intracellular interaction of human immunodeficiency virus type 1 (ARV- 2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. J Virol 1990, 64:6297-6304.
19. Chen BK, Gandhi RT, Baltimore D: CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol 1996, 70:6044-6053.
20. Benson RE, Sanfridson A, Ottinger JS, Doyle C, Cullen BR: Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med 1993, 177:1561-1566.
21. Palese P, Tobita K, Ueda M, Compans R: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61:397-410.
22. Shibata S, Yamamoto-Goshima F, Maeno K, Hanaichi T, Fujita Y, Nakajima K, et al.: Characterization of a temperature-sensitive influenza B virus mutant defective in neuraminidase. J Virol 1993, 67:3264-3273.
23. Liu C, Eichelberger MC, Compans RW, Air GM: Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995, 69:1099-1106.
24. Haughn L, Gratton S, Caron L, Sekaly RP, Veillette A, Julius M: Association of tyrosine kinase p561ck with CD4 inhibits the induction of growth through the alpha beta T-cell receptor. Nature 1992, 358:328-331.
25. Marshall WL, Diamond DC, Kowaski MM, Finberg RW: High level of surface CD4 prevents stable human immunodeficiency virus infection of T-cell transfectants. J Virol 1992, 66:5492-5499.
26. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, et al: In vio gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
27. Naldini L, Blomer U, Gage FH, Trono D, Verma IM: Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996, 93:11382-11388.
28. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnol 1997, 15:871-875.
29. Deng H, Lliu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661 -666.
30. Aiken C: Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997, 71:5871-5877.
31. Moebius U, Clayton LK, Abraham S, Diener A, Yunis J, Harrison S, Reinherz EL, et al.: Human immunodeficiency virus gp120 binding C′C″ ridge of CD4 domain 1 is also involved in interaction with class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1992, 89:12008-12012.
32. Veillette A, Bookman MA, Horak EM, Bolen JB: The CD4 and CD8 Cell surface antigens are associated with the internal membrane tyrosine -protein kinase p56lck. Cell 1988, 55:301-308.
33. Shaw AS, Amrein KE, Hammond C, Stern DF, Sefton BM, Rose JK: The Lck tyrosine protein kinase interacts with the cytoplasmic tail of the CD4 glycoprotein through its unique amino terminal domain. Cell 1989, 59:627-636.
34. Turner J, Brodsky MH, Irving BA, Levin SD, Perlmutter RM, Littman DR: Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell 1990, 60:755-765.
35. Garcia JV, Alfano J, Miller AD: The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4. J Virol 1993, 67:1511 -1516.
36. Lenburg ME, Landau NR: Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol 1993, 67:7238-7245.
37. Vincent MJ, Raja NU, Jabbar MA: Human immunodeficiency virus type 1 Vpu protein induces degradation of chimeric envelope glycoproteins bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic domain in Vpu-induced degradation in the endoplasmic reticulum. J Virol 1993, 67:5538-5549.
38. Bour S, Geleziunas R, Wainberg MA: The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev 1995, 59:63-93.
39. Mangasarian A, Foti M, Aiken C, Chin D, Carpentier JL, Trono D: The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane. Immunity 1997, 6:67-77.
40. Chen YL, Trono D, Camaur D: The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol 1998, 72:3178-3184.
41. Aiken C, Trono D: Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995, 69:5048-5056.
42. Chowers MY, Pandori MW, Spina CA, Richman DD, Guatelli JC: The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 1995, 212:451-457.
43. Schwartz O, Maréchal V, Danos O, Heard JM: Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 1995, 69:4053-4059
44. Rubin H: A virus in chick embryos which induces resistance to in vitro infection with Rous sarcoma virus. Proc Natl Acad Sci USA 1960, 4:1105-1119.
45. Rubin H: The nature of a virus-induced resistance of Rous Sarcoma virus. Virology 1961, 13:200-206.
46. Weiss R: Experimental Biology and Assays of Retroviruses. New York:Cold Spring Harbor Press; 1982.
47. Coffin J: Retroviridae: the viruses and their replication. In Fields Virology. Edited by Fields B, Knipe D and Howley P. Philadelphia: Lipincott-Raven; 1996: 1767-1847.
48. Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD: Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA 1988, 85:9580-9584.
49. Earl PL, Moss B, Doms RW: Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol 1991, 65:2047-2055.
50. Rowell JF, Stanhope PE, Siliciano RF: Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol 1995, 155:473-488.
51. Ohno H, Aguilar RC, Fournier MC, Hennecke S, Cosson P, Bonifacino JS: Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 1997, 238:305-315.
52. Schwartz O, Rivière Y, Heard JM, Danos O: Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef. J Virol 1993, 67:3274-3280.
53. Dorfman T, Mammano F, Haseltine WA, Gottlinger HG: Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1994, 68:1689-1696.
54. Freed EO, Martin MA: Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995, 69:1984-1989.
55. Cosson P: Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J 1996, 15:5783-5788.
56. Harder T, Simons K: Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 1997, 9:534-542.
57. Harder T, Scheiffele P, Verkade P, Simons K: Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 1998,141:929-942.
58. Xavier R, Brennan T, Li Q, McCormack C, Seed B: Membrane compartmentation is required for efficient T-cell activation. Immunity 1998, 8:723-732.
59. Miller MD, Feinberg MB, Greene WC: The HIV-1 nef gene acts as a positive viral infectivity factor. Trends Microbiol 1994, 2:294-298.
60. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD: The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 1994, 179:115-123.
61. Umesono K, Murakami K, Thompson C, Evans R: Direct repeats as selective response elements for the thyroid hormone, retinoic acid and vitamin D3 receptors. Cell 1991, 65:1255-1266.
62. Trono D, Feinberg MB, Baltimore D: HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989, 59:113-120.
63. Charneau P, Mirambeau G, Roux P, Paulus S, Bue H, Clavel F: HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994, 241:651-662.
64. Gervaix A, Gervaix A, West D, Leoni L, Richman D, Wong-Staal F, Corbeil J: A new cell line to monitor HIV-1 infection and drug susceptibility in vitro. Proc Natl Acad Sci USA 1997, 94:4653-4658.
65. Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, et al.: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994, 68:3015-3026.
66. Aiken C, Krause L, Chen YL, Trono D: Mutational analysis of HIV-1 Nef: identification of two mutants that are temperature-sensitive for CD4 downregulation. Virology 1996, 217:293-300.